Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease
Prospective in Vivo Ultra-high-performance PET Imaging of Synaptic Density, Reactive Astrogliosis and Tau Accumulation in Alzheimer's Disease, Healthy Controls and Centenarians and Relationship With Fluid Biomarkers
AIM: to investigate the relationship between synaptic density, tau and reactive astrogliosis in Alzheimer's disease (AD) versus healthy controls and centenarians.
DESIGN: this cross-sectional study will recruit patients with biomarker-proven AD, age- and sex-matched healthy controls as well as centenarians. All subjects will undergo a neuropsychological evaluation and ultra-high-performance PET imaging sessions with 18F-SynVesT-1 (synaptic density), 18F-MK6240 (tau) and 18F-SMBT-1 (reactive astrogliosis) as well as structural and diffusion MRI. Blood samples will be taken for the evaluation of blood-based biomarkers.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgio, 3000
- University Hospitals Leuven
-
Contatto:
- Koen Van Laere, Prof.
- Numero di telefono: +3216343715
- Email: koen.vanlaere@uzleuven.be
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients with Alzheimer's disease will be recruited from the memory clinic of the University Hospitals Leuven (UZ Leuven). Centenarians will be recruited from the 100-plus study at UMC Amsterdam. Healthy controls will be recruited through internet advertisements.
Descrizione
- Patients with Alzheimer's disease (AD)
Inclusion Criteria:
- Patient has a clinical diagnosis of biomarker proven AD (prodromal AD or dementia due to AD).
- Patient has an mini-mental state examination (MMSE) score of 15 or higher.
- Patient or legal representative is able to understand the patient information brochure and give written informed consent.
Exclusion Criteria:
- Patient has a history of any major other disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator.
- Patient is on anti-amyloid therapy.
- Patient has contra indications for magnetic resonance imaging (MRI).
- Patient is a current smoker.
- Patient is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
Healthy control participants
Inclusion Criteria:
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- Participant is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs, clinical laboratory test and urinalysis.
- No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment (Geriatric depression scale (GDS) and Beck's depression inventory (BDI)).
- A normal structural MRI scan with respect to the participant's age as assessed by expert radiologist.
- Participant has to be at least 40 years old
Exclusion Criteria:
- Participant has a history of any major disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator (especially diabetes mellitus, heart disease, liver and kidney disease, or most forms of cancer).
- Participant is a smoker or has a recent history of smoking.
- Participant has a history or evidence of psychiatric disease.
- Participant is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
- Participant has a contra-indication for MRI scanning.
- Participant suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures. Subject cannot lie still for at least 30 minutes inside a scanner.
- Participant does not understand the study procedures.
- Participant is unwilling or unable to perform all of the study procedures or is considered unsuitable in any way by the principal investigator.
- Participant is pregnant or is breastfeeding.
Centenarians
Inclusion Criteria:
- Participant is included in the 100-plus study at Amsterdam UMC.
- Participant or legal representative is able to understand the information brochure and give written informed consent.
Exclusion Criteria:
- Participant has a history of any major disease that may interfere with the investigations or make the subject unfit for participation according to the interpretation by the investigator (especially diabetes mellitus, heart disease, liver and kidney disease, or most forms of cancer).
- Participant is a current smoker.
- Participant is currently a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
- Participant has contra indications for MRI or cannot lie still in the scanner for 30 minutes.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_CONTROL
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Partecipanti sani al controllo
|
Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner. |
|
Patients with AD
|
Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner. |
|
Centenarians
|
Ultra-high-performance positron emission tomography (PET) of monoamine oxidase B (MAO-B) using the radioligand 18F-SMBT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of synaptic vesicle glycoprotein 2A (SV2A, synaptic density) using the radioligand 18F-SynVesT-1 on the NeuroEXPLORER PET scanner. Ultra-high-performance positron emission tomography (PET) of tau neurofibrillary tangles using the radioligand 18F-MK6240 on the NeuroEXPLORER PET scanner. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The correlation between tau, synaptic density and reactive astrogliosis
Lasso di tempo: Baseline
|
Mediation and correlation analyses will be performed to investigate the correlation between tau, synaptic density and reactive astrogliosis PET measures as quantified by standardized uptake value ratios (SUVR). |
Baseline
|
|
Changes in synaptic density, tau and reactive astrolgiosis between AD patients, controls and centenarians
Lasso di tempo: Baseline
|
Synaptic density, tau and reactive astrolgiosis PET measures, as quantified by standardized uptake value ratios (SUVR), will be compared across the three different groups: patients with AD, healthy control participants and centenarians. |
Baseline
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation of synaptic density, tau and reactive astrogliosis with diffusion MRI
Lasso di tempo: Baseline
|
The correlation of synaptic density, tau and reactive astrolgiosis PET, as quantified by standardized uptake value ratios (SUVR) in typical regions, with diffusion MRI metrics (fibre density and fibre cross-section) in the connecting white matter bundles will be assessed. |
Baseline
|
|
Correlation of synaptic density, tau and reactive astrogliosis with blood-based biomarkers
Lasso di tempo: Baseline
|
The correlation of synaptic density, tau and reactive astrogliosis PET measures, as quantified by standardized uptake value ratios (SUVR), with blood-based markers of synaptic integrity and reactive astrogliosis will be assessed. |
Baseline
|
|
Correlation of synaptic density, tau and reactive astrogliosis with cognitive performance
Lasso di tempo: Baseline
|
The correlation of synaptic density, tau and reactive astrolgiosis PET measures, as quantified by standardized uptake value ratios (SUVR), with neuropsychological test scores will be assessed. |
Baseline
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- S72313
- SAO-FRA20250007 (Altro numero di sovvenzione/finanziamento: Belgian Alzheimer Research Foundation)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .